Theranostic Heterodimeric Prodrug with Dual‐Channel Fluorescence Turn‐On and Dual‐Prodrug Activation for Synergistic Cancer Therapy
Authors:
Open Access
- 28 August 2021
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (21) , 2101144
Abstract
Theranostic prodrugs that can precisely monitor drug activation with synergistic therapeutic effects are highly desirable for personalized medicine. In this study, a theranostic heterodimeric prodrug, CyNH‐SS‐DOX, with synchronous and independent dual‐channel fluorescence turn‐on and dual‐prodrug activation for synergistic cancer therapy is developed. A hemicyanine fluorescent drug, CyNH2, with good therapeutic effects found in this work, is conjugated to doxorubicin (DOX) through a disulfide linker to form CyNH‐SS‐DOX. Before activation, both the fluorescence of DOX and CyNH2 are in the off state and the toxicity is low. In the presence of intracellular glutathione, both the fluorescence of DOX and CyNH2 at different channels are turned on. Meanwhile, DOX and CyNH2 are activated in a synergistic anticancer effect. It is believed that CyNH‐SS‐DOX is promising for monitoring prodrug activation in dual‐fluorescence channels and for enhancing therapeutic efficacy with few side effects.Keywords
Funding Information
- National Natural Science Foundation of China (51873072, 52073101)
- Guangdong Provincial Pearl River Talents Program (2019QN01Y088)
This publication has 29 references indexed in Scilit:
- Cancer nanomedicine: progress, challenges and opportunitiesNature Reviews Cancer, 2016
- Versatile Prodrug Nanoparticles for Acid‐Triggered Precise Imaging and Organelle‐Specific Combination Cancer TherapyAdvanced Functional Materials, 2016
- Dual-channel NIR activatable theranostic prodrug for in vivo spatiotemporal tracking thiol-triggered chemotherapyChemical Science, 2016
- Recent advances of cocktail chemotherapy by combination drug delivery systemsAdvanced Drug Delivery Reviews, 2016
- Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug–Drug Conjugate for Cancer TherapyJournal of the American Chemical Society, 2014
- In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic ProdrugJournal of the American Chemical Society, 2014
- Stimuli-responsive nanocarriers for drug deliveryNature Materials, 2013
- Multifunctional nanoparticles for multimodal imaging and theragnosisChemical Society Reviews, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007